

**Jubilant Life Sciences (Shanghai) Limited**  
Balance sheet as at 31 March 2017

	Notes No	As at 31 March 2017		As at 31 March 2016		As at 1 April 2015	
		RMB	INR (' In Thousands)	RMB	INR (' In Thousands)	RMB	INR (' In Thousands)
<b>ASSETS</b>							
<b>Non-current assets</b>							
Property, plant and equipments	1	94,226	887	141,265	1,449	179,003	1,804
Financial assets							
Long-term loans and advances	2	-	-	123,381	1,266	98,334	991
<b>Total non-current assets</b>		<b>94,226</b>	<b>887</b>	<b>264,646</b>	<b>2,715</b>	<b>277,337</b>	<b>2,795</b>
<b>Current assets</b>							
Inventories	3	11,240,210	105,770	10,802,233	110,831	25,008,005	252,081
Financial Assets							
Trade receivables	4	14,048,947	132,201	3,301,794	39,876	10,815,224	109,017
Cash and cash equivalents	5	7,217,629	67,918	12,199,987	125,172	12,399,989	124,992
Short-term loans and advances	6	-	-	-	-	<del>427,607</del>	4,311
Other financial assets	7	10,378,333	97,660	19,592,707	201,021	40,595,858	409,207
Other current assets	8	1,436,627	13,518	3,853,396	39,536	5,074,755	51,154
<b>Total current assets</b>		<b>44,321,746</b>	<b>417,067</b>	<b>49,750,117</b>	<b>510,436</b>	<b>94,321,438</b>	<b>950,762</b>
<b>Total assets</b>		<b>44,415,972</b>	<b>417,954</b>	<b>50,014,763</b>	<b>513,151</b>	<b>94,598,775</b>	<b>953,557</b>
<b>EQUITY AND LIABILITIES</b>							
<b>Equity</b>							
Equity share capital	9	1,652,837	8,804	1,652,837	8,804	1,652,837	8,804
Other equity	10	20,451,955	199,202	17,359,264	186,259	19,827,406	207,718
<b>Total equity</b>		<b>22,104,792</b>	<b>208,006</b>	<b>19,012,101</b>	<b>195,063</b>	<b>21,480,243</b>	<b>216,522</b>
<b>Liabilities</b>							
<b>Current liabilities</b>							
Financial liabilities							
Trade payables	11	22,267,346	209,536	30,930,086	317,343	72,917,748	735,011
Other financial liabilities							
Other current liabilities	12	43,834	412	72,576	745	143,125	1,443
Current tax liabilities(Net)	13	-	-	-	-	57,659	581
<b>Total current liabilities</b>		<b>22,311,180</b>	<b>209,948</b>	<b>31,002,662</b>	<b>318,088</b>	<b>73,118,532</b>	<b>737,035</b>
<b>Total Equity and Liabilities</b>		<b>44,415,972</b>	<b>417,954</b>	<b>50,014,763</b>	<b>513,151</b>	<b>94,598,775</b>	<b>953,557</b>

Prakash C Bisht  
CFO (LSI) & Senior VP (Group Accounts)  
Place: Noida  
Date: 23 May, 2017

Jubilant Life Sciences (Shanghai) Limited  
Statement of Profit and Loss for the financial year ended 31 March 2017

	Notes No	For the year ended on 31 March 2017		For the year ended on 31 March 2016	
		RMB	INR (' In Thousands)	RMB	INR (' In Thousands)
<b>REVENUE</b>					
Revenue from operations (Gross)	14	103,959,379	1,035,846	128,950,500	1,324,574
Other Income	15	45,683	457	48,780	500
<b>Total revenue</b>		<b>104,005,062</b>	<b>1,036,303</b>	<b>128,999,280</b>	<b>1,325,074</b>
<b>EXPENSES</b>					
Purchase of stock-in-trade	16	88,566,396	881,295	100,067,591	1,028,364
Change in Inventories of finished goods and Traded Goods	17	(407,666)	(2,807)	14,589,163	149,355
Employee benefits expenses	18	5,208,526	51,897	6,991,500	71,900
Finance costs	19	305,924	3,023	385,216	3,948
Depreciation	1	30,277	302	37,738	388
Other expenses	20	7,208,914	72,021	9,306,697	95,739
<b>Total expenses</b>		<b>100,912,371</b>	<b>1,005,731</b>	<b>131,377,905</b>	<b>1,349,694</b>
<b>Profit/(loss) before tax</b>		<b>3,092,691</b>	<b>30,572</b>	<b>(2,378,625)</b>	<b>(24,620)</b>
Tax expenses:					
- Current tax		-	-	-	-
- Deferred tax charge/(credit)		-	-	-	-
<b>Profit/ (loss) for the Year</b>		<b>3,092,691</b>	<b>30,572</b>	<b>(2,378,625)</b>	<b>(24,620)</b>
<b>Items that will be reclassified to profit or loss</b>					
Exchange differences on translation of foreign operations		-	(17,332)	-	(51,189)
<b>Total other comprehensive Income, net of tax</b>		<b>-</b>	<b>(17,332)</b>	<b>-</b>	<b>(51,189)</b>
<b>Total comprehensive income for the year</b>		<b>3,092,691</b>	<b>13,240</b>	<b>(2,378,625)</b>	<b>(75,809)</b>
<b>Profit attributable to:</b>					
Owners of the company		3,092,691	30,572	(2,378,625)	(24,620)
Non-controlling Interest		-	-	-	-
<b>Total comprehensive Income attribute to:</b>					
Owners of the company		3,092,691	13,240	(2,378,625)	(75,809)
Non-controlling Interest		-	-	-	-
		<b>3,092,691</b>	<b>13,240</b>	<b>(2,378,625)</b>	<b>(75,809)</b>

Prakash C Bisht  
CFO (LSI) & Senior VP (Group Accounts)  
Place: Noida  
Date: 23 May, 2017

Jub Life Sciences (Shanghai) Ltd  
Cash flow statement for the Year ended on 31 March 2017

Particulars	For the year ended 31 March 2017		For the year ended 31 March 2016	
	RMB	INR (' In Thousands)	RMB	INR (' In Thousands)
<b>A. Cash flow from operating activities</b>				
Net profit/(Loss) before tax	3,092,691	30,572	(2,378,625)	(24,620)
Adjustments :				
Depreciation	30,277	302	37,738	388
Loss on sale/ disposal/ discard/ Impairment of fixed assets (net)	19,562	190	-	-
Finance costs	305,924	3,023	385,216	3,948
Interest Income	(43,350)	(433)	(47,887)	(492)
Unrealised foreign exchange (including mark-to-market on currency and interest rate swaps)	(61,085)	(594)	(119,630)	(1,232)
<b>Operating cash flow before working capital changes</b>				
Decrease in trade receivable, other non-current assets, current assets and other financial assets	1,000,367	9,734	30,140,500	308,940
Increase)/ Decrease in Inventories	(437,977)	(4,262)	14,205,772	145,609
Increase in trade payables and current liabilities	(8,623,393)	(83,906)	(42,028,098)	(430,786)
<b>Cash generated from operations</b>	(4,716,984)	(45,374)	194,986	1,755
Income tax paid (net of refund)	-	-	(57,659)	(591)
<b>Net cash generated from operating activities</b>	(4,716,984)	(45,374)	137,327	1,164
<b>B. Cash flow from Investing activities</b>				
Acquisition/ purchase of property, plant and equipment	(2,800)	(27)	-	-
Interest received	43,350	433	47,887	492
<b>Net cash used in Investing activities</b>	40,550	406	47,887	492
<b>C. Cash flow arising from financing activities</b>				
Finance costs paid	(305,924)	(3,047)	(385,216)	(3,948)
<b>Net cash used in financing activities</b>	(305,924)	(3,047)	(385,216)	(3,948)
<b>D. Effect of exchange rate changes</b>				
Net decrease in cash and cash equivalents (A+B+C+D)	(4,982,358)	(57,254)	(200,002)	180
Add: cash and cash equivalents at the beginning of year	12,199,987	125,172	12,399,989	124,992
<b>Cash and cash equivalents at the end of the year</b>	7,217,629	67,918	12,199,987	125,172
<i>Reconciliation of cash and cash equivalents as per the cash flow statement</i>				
Cash and cash equivalents	7,217,629	67,918	12,199,987	125,172
Bank overdrafts				
<b>Balances per statement of cash flows</b>	7,217,629	67,918	12,199,987	125,172

Prakash C Bisht  
CFO (LSI) & Senior VP (Group Accounts)  
Place: Noida  
Date: 23 May, 2017

Jubilant Life Sciences (Shanghai) Limited  
Note 1 Property, plant and equipment

Description	RMB					INR (' In Thousands)		
	Furniture & fixtures	Office Equipment	Computers	Total	Furniture & fixtures	Office Equipment	Computers	Total
<b>Gross carrying amount</b>								
Deemed cost as at 1 April 2015	34,614	139,551	4,838	179,003	349	1,407	48	1,804
Additions / adjustments	-	-	-	-	-	-	-	-
Deductions / adjustments	-	-	-	-	-	-	-	-
Currency translation adjustment	-	-	-	-	9	64	1	74
<b>Gross carrying amount as at 31 March 2016</b>	<b>34,614</b>	<b>139,551</b>	<b>4,838</b>	<b>179,003</b>	<b>358</b>	<b>1,471</b>	<b>49</b>	<b>1,878</b>
<b>Accumulated depreciation as at 1 April 2015</b>								
Depreciation charge for the year	7,922	29,816	-	37,738	81	307	-	388
Currency translation adjustment	-	-	-	-	3	38	-	41
<b>Accumulated depreciation as at 31 March 2016</b>	<b>7,922</b>	<b>29,816</b>	<b>-</b>	<b>37,738</b>	<b>84</b>	<b>345</b>	<b>-</b>	<b>429</b>
<b>Net carrying amount as at 31 March 2016</b>	<b>26,692</b>	<b>109,735</b>	<b>4,838</b>	<b>141,265</b>	<b>274</b>	<b>1,126</b>	<b>49</b>	<b>1,449</b>
<b>Net carrying amount as at 1 April 2015</b>	<b>34,614</b>	<b>139,551</b>	<b>4,838</b>	<b>179,003</b>	<b>349</b>	<b>1,407</b>	<b>48</b>	<b>1,804</b>

Description	RMB					INR (' In Thousands)		
	Furniture & fixtures	Office Equipment	Computers	Total	Furniture & fixtures	Office Equipment	Computers	Total
<b>Gross carrying amount</b>								
Deemed cost as at 1 April 2016	34,614	139,551	4,838	179,003	358	1,471	49	1,878
Additions / adjustments	3,200	-	-	3,200	31	-	-	31
Deductions / adjustments	(16,441)	(7,306)	-	(23,747)	(160)	(72)	-	(232)
Currency translation adjustment	-	-	-	-	(34)	(302)	18	(318)
<b>Gross carrying amount as at 31 March 2017</b>	<b>21,373</b>	<b>132,245</b>	<b>4,838</b>	<b>158,456</b>	<b>195</b>	<b>1,097</b>	<b>67</b>	<b>1,359</b>
<b>Accumulated depreciation as at 1 April 2016</b>								
Depreciation charge for the year	7,922	29,816	-	37,738	84	345	-	429
Deductions / adjustments	6,616	23,662	-	30,277	66	236	-	302
Currency translation adjustment	(3,786)	-	-	(3,786)	(38)	-	-	(38)
<b>Accumulated depreciation as at 31 March 2017</b>	<b>10,752</b>	<b>53,478</b>	<b>-</b>	<b>64,229</b>	<b>94</b>	<b>359</b>	<b>19</b>	<b>472</b>
<b>Net carrying amount as at 31 March 2017</b>	<b>10,621</b>	<b>78,767</b>	<b>4,838</b>	<b>94,226</b>	<b>101</b>	<b>738</b>	<b>48</b>	<b>887</b>
<b>Net carrying amount as at 1 April 2016</b>	<b>26,692</b>	<b>109,735</b>	<b>4,838</b>	<b>141,265</b>	<b>274</b>	<b>1,126</b>	<b>49</b>	<b>1,449</b>

Jubilant Life Sciences (Shanghai) Limited

Notes to financial statement for the year ended 31 March 2017

	As at 31 March 2017		As at 31 March 2016		As at 1 April 2015	
	RMB	INR (' In Thousands)	RMB	INR (' In Thousands)	RMB	INR (' In Thousands)
<b>Note 11. TRADE PAYABLES</b>						
Trade payables-others	22,267,346	209,536	30,930,086	317,343	72,917,748	735,011
	<b>22,267,346</b>	<b>209,536</b>	<b>30,930,086</b>	<b>317,343</b>	<b>72,917,748</b>	<b>735,011</b>
<b>Note 12. OTHER CURRENT LIABILITIES</b>						
Statutory Dues	43,834	412	72,576	745	143,125	1,443
	<b>43,834</b>	<b>412</b>	<b>72,576</b>	<b>745</b>	<b>143,125</b>	<b>1,443</b>
<b>Note 13. CURRENT TAX LIABILITIES(NET)</b>						
Provision for income tax	-	-	-	-	57,659	581
	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>57,659</b>	<b>581</b>
<b>FINANCIAL ASSETS NON CURRENT</b>						
<b>Note 2. LONG TERM LOANS AND ADVANCES</b> (Unsecured and considered good)						
Security deposits	-	-	123,381	1,266	98,334	991
	<b>-</b>	<b>-</b>	<b>123,381</b>	<b>1,266</b>	<b>98,334</b>	<b>991</b>
<b>Note 3. INVENTORIES</b> (Valued at lower of cost and net realisable value)						
- Stock-in-trade	11,240,210	105,770	10,802,233	110,831	25,008,005	252,081
	<b>11,240,210</b>	<b>105,770</b>	<b>10,802,233</b>	<b>110,831</b>	<b>25,008,005</b>	<b>252,081</b>
<b>FINANCIAL ASSET CURRENT</b>						
<b>Note 4. TRADE RECEIVABLES</b>						
Other receivables						
Unsecured, considered good	14,048,947	132,201	3,301,794	33,876	10,815,224	109,017
<b>Total</b>	<b>14,048,947</b>	<b>132,201</b>	<b>3,301,794</b>	<b>33,876</b>	<b>10,815,224</b>	<b>109,017</b>
<b>Note 5. CASH AND CASH EQUIVALENTS</b>						
<b>Cash and cash equivalents</b>						
Balances with banks:						
- On current accounts	7,217,506	67,917	12,197,040	125,142	12,397,519	124,967
Cash on hand	123	1	2,947	30	2,470	25
	<b>7,217,629</b>	<b>67,918</b>	<b>12,199,987</b>	<b>125,172</b>	<b>12,399,989</b>	<b>124,992</b>
<b>Note 6. SHORT TERM LOANS AND ADVANCES</b> (Unsecured and considered good)						
- Deposits	-	-	-	-	109,873	1,108
- Loans and advances to employees	-	-	-	-	317,734	3,203
	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>427,607</b>	<b>4,311</b>
<b>Note 7. OTHER FINANCIAL ASSETS</b>						
Notes B/R Receivable	9,890,160	93,066	19,316,893	198,191	40,527,063	408,513
Others	488,173	4,594	275,814	2,830	68,795	694
	<b>10,378,333</b>	<b>97,660</b>	<b>19,592,707</b>	<b>201,021</b>	<b>40,595,858</b>	<b>409,207</b>
<b>Note 8. OTHER CURRENT ASSETS</b>						
Deposit /balance with excise & sales tax-current	1,241,578	11,683	3,685,192	37,810	4,804,038	48,425
Advance For Supply Of Goods & Services	-	-	-	-	516	5
Prepaid expenses	195,049	1,835	168,204	1,726	270,201	2,724
	<b>1,436,627</b>	<b>13,518</b>	<b>3,853,396</b>	<b>39,536</b>	<b>5,074,755</b>	<b>51,154</b>

**Jubilant Life Sciences (Shanghai) Limited**

**Notes to financial statement for the year ended 31 March 2017**

	As at 31 March 2017		As at 31 March 2016		As at 1 April 2015	
	RMB	INR (' In Thousands)	RMB	INR (' In Thousands)	RMB	INR (' In Thousands)
<b>Note 9. SHARE CAPITAL</b>						
<b>Authorized</b>						
200,000 (31 March 2016; 200,000; 1 April 2015; 200,000 equity shares with USD 1 par value)	1,652,837	8,804	1,652,837	8,804	1,652,837	8,804
	<b>1,652,837</b>	<b>8,804</b>	<b>1,652,837</b>	<b>8,804</b>	<b>1,652,837</b>	<b>8,804</b>
<b>Issued and subscribed</b>						
200,000 (31 March 2016; 200,000; 1 April 2015; 200,000 equity shares with USD 1 par value)	1,652,837	8,804	1,652,837	8,804	1,652,837	8,804
	<b>1,652,837</b>	<b>8,804</b>	<b>1,652,837</b>	<b>8,804</b>	<b>1,652,837</b>	<b>8,804</b>
<b>Paid up</b>						
200,000 (31 March 2016; 200,000; 1 April 2015; 200,000 equity shares with USD 1 par value)	1,652,837	8,804	1,652,837	8,804	1,652,837	8,804
	<b>1,652,837</b>	<b>8,804</b>	<b>1,652,837</b>	<b>8,804</b>	<b>1,652,837</b>	<b>8,804</b>

**Movement in equity share capital**

	As at 31 March 2017		As at 31 March 2016		As at 1 April 2015	
	Number	INR (' In Thousands)	Number	INR (' In Thousands)	Number	INR (' In Thousands)
At the commencement and at the end of the year	200,000	8,804	200,000	8,804	200,000	8,804

**Terms and rights attached to equity shares**

The Company has only one class of shares referred to as equity shares having par value of USD 1 each. Each holder of equity shares is entitled to one vote per share. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amounts. However, no such preferential amounts exist currently. The distribution will be in proportion to the number of equity shares held by the shareholders.

Out of the equity Shares issued by the company, shares held by it's holding company/ultimate holding company and/or their subsidiaries/associates are as below:

Name of the shareholder	As at 31 March 2017		As at 31 March 2016		As at 1 April 2015	
	RMB	INR (' In Thousands)	RMB	INR (' In Thousands)	RMB	INR (' In Thousands)
Jubilant Pharma Limited - Singapore	-	-	1,652,837	8,804	1,652,837	8,804
Jubilant Life Sciences International Pte. Ltd., Singapore	1,652,837	8,804	-	-	-	-

**The details of shareholders holding more than 5% shares in the company**

Name of the shareholder	As at 31 March 2017		As at 31 March 2016		As at 1 April 2015	
	Number	% of total shares	Number	% of total shares	Number	% of total shares
Jubilant Pharma Limited - Singapore	-	-	1,652,837	100%	1,652,837	100%
Jubilant Life Sciences International Pte. Ltd., Singapore	1,652,837	100%	-	-	-	-

Jubilant Life Sciences (Shanghai) Limited

Notes to financial statement for the year ended 31 March 2017

	As at 31 March 2017		As at 31 March 2016		As at 1 April 2015	
	RMB	INR (' In Thousands)	RMB	INR (' In Thousands)	RMB	INR (' In Thousands)
<b>Note 10. OTHER EQUITY RESERVES AND SURPLUS</b>						
<b>Capital Reserve</b>						
Additions/Adjustment during the year	64,300	626	-	-	-	-
	<b>64,300</b>	<b>626</b>	-	-	-	-
<b>Retained earnings</b>						
Opening balance	15,013,780	160,757	17,392,405	185,377	28,266,804	296,485
Add: Net Profit after tax transferred from Statement of Profit and Loss	3,092,691	30,572	(2,378,625)	(24,620)	(10,142,858)	(103,792)
Amount available for appropriation	<b>18,106,471</b>	<b>191,329</b>	<b>15,013,780</b>	<b>160,757</b>	<b>18,123,946</b>	<b>192,693</b>
Less: Appropriations						
Transfer to capital Reserves	64,300	626	-	-	-	-
Transfer to Legal Reserves	-	-	-	-	731,541	7,316
	<b>18,042,171</b>	<b>190,703</b>	<b>15,013,780</b>	<b>160,757</b>	<b>17,392,405</b>	<b>185,377</b>
<b>Statutory reserve</b>						
Opening balance	2,345,484	21,419	2,435,001	22,341	1,829,655	16,287
Additions/Adjustment during the year	-	-	-	-	731,541	7,316
Deductions/Adjustment during the year	-	-	89,517	922	-	-
Charged during the year(profit and loss)	-	-	-	-	(126,195)	(1,262)
	<b>2,345,484</b>	<b>21,419</b>	<b>2,345,484</b>	<b>21,419</b>	<b>2,435,001</b>	<b>22,341</b>
<b>3. OTHER COMPONENT OF EQUITY</b>						
<b>Exchange differences on translation of foreign operations</b>						
At the commencement of the year	-	4,083	-	-	-	-
Addition/(deduction) during the year	-	(17,629)	-	4,083	-	-
At the end of the year	-	<b>(13,546)</b>	-	<b>4,083</b>	-	-
	<b>20,451,955</b>	<b>199,202</b>	<b>17,359,264</b>	<b>186,259</b>	<b>19,827,406</b>	<b>207,718</b>

**Jubilant Life Sciences (Shanghai) Limited**
**Notes to financial statement for the year ended 31 March 2017**

	For the year ended on 31 March 2017		For the year ended on 31 March 2016	
	RMB	INR (' In Thousands)	RMB	INR (' In Thousands)
<b>Note 14. REVENUE FROM OPERATIONS</b>				
Sales of products	103,958,929	1,035,841	128,894,825	1,324,001
Other operating revenue	450	5	55,675	573
<b>Revenue from operations(gross)</b>	<b>103,959,379</b>	<b>1,035,846</b>	<b>128,950,500</b>	<b>1,324,574</b>
<b>Revenue from operations(net)</b>	<b>103,959,379</b>	<b>1,035,846</b>	<b>128,950,500</b>	<b>1,324,574</b>
<b>Note 15. OTHER INCOME</b>				
Interest Income	43,350	433	47,887	492
Other non-operating Income	2,333	24	893	8
	<b>45,683</b>	<b>457</b>	<b>48,780</b>	<b>500</b>
<b>Note 16. PURCHASE OF STOCK-IN-TRADE</b>				
Purchase of stock-in-trade	88,566,396	881,295	100,067,591	1,028,364
	<b>88,566,396</b>	<b>881,295</b>	<b>100,067,591</b>	<b>1,028,364</b>
<b>Note 17. CHANGE IN INVENTORIES OF FINISHED GOODS AND TRADED GOODS</b>				
Stock at close -Traded goods	11,267,975	114,017	10,516,613	107,226
	11,267,975	114,017	10,516,613	107,226
Stock at commencement -Traded goods	10,860,309	111,210	25,105,776	256,581
	10,860,309	111,210	25,105,776	256,581
Increase/ (Decrease) In Stocks	407,666	2,807	(14,589,163)	(149,355)
<b>Note 18. EMPLOYEE BENEFITS EXPENSES</b>				
Salaries, wages, bonus, gratuity and allowances	3,736,556	37,270	5,148,885	52,953
Contribution to provident and superannuation fund	418,941	4,177	660,702	6,791
Staff welfare expenses	1,053,029	10,450	1,181,913	12,156
	<b>5,208,526</b>	<b>51,897</b>	<b>6,991,500</b>	<b>71,900</b>
<b>Note 19. FINANCE COSTS</b>				
Interest expense	305,924	3,023	385,216	3,948
	305,924	3,023	385,216	3,948
<b>Note 20. OTHER EXPENSE</b>				
Rent	468,349	4,716	703,196	7,232
Rates and taxes	246,280	2,439	173,417	1,782
Insurance	60,555	601	77,169	793
Advertisement, publicity and sales promotion	18,463	184	56,529	582
Travelling and other incidental expenses	241,564	2,413	445,165	4,576
Repairs				
- Others	3,075	31	5,655	58
Office expenses	121,245	1,214	211,097	2,170
Printing and stationery	5,210	52	10,214	105
Communication expenses	196,782	1,965	294,606	3,029
Staff recruitment and training	-	-	20,408	210
Auditors Remuneration - As Auditors	64,594	645	110,172	1,132
Legal, professional and consultancy charges	138,193	1,381	600,597	6,172
Freight and forwarding (Including ocean freight)	2,090,120	20,754	2,130,290	21,904
Subscription	81,270	806	129,199	1,330
Miscellaneous expenses	-	-	1,073	11
Bank charges	88,638	884	234,331	2,408
Discounts and claims to customer and other selling expenses	507,300	5,060	683,667	7,022
Commission on sales	442,018	4,439	896,668	9,227
Loss on sale/disposal of fixed Assets(net)	19,562	190	-	-
Foreign Exchange Gain/Loss	2,415,696	24,247	2,523,244	25,996
	<b>7,208,914</b>	<b>72,021</b>	<b>9,306,697</b>	<b>95,739</b>